They are:
- Humira — $21.4 billion
- Eliquis — $9.9 billion
- Enbrel — $8.1 billion
- Stelara — $6.6 billion
- Keytruda — $6.5 billion
- Trulicity — $6.5 billion
- Januvia — $6 billion
- Xarelto — $6 billion
- Biktarvy — $5.1 billion
- Remicade — $4.7 billion
- Opdivo — $4.4 billion
- Rituxan — $4.3 billion
- Lantus Solostar — $4.3 billion
- Symbicort — $3.9 billion
- Jardiance — $3.9 billion
- Genvoya — $3.8 billion
- Tecfidera — $3.8 billion
- Vyvanse — $3.7 billion
- Victoza 3-pak — $3.6 billion
- Ibrance — $3.6 billion
Find the full report here.
More articles on pharmacy:
CVS HealthHub rollout resumes
Merck bets on one-shot vaccine
Virginia pharmacy school files suit against accreditation agency, calls process ‘bizarrely contradictory and Kafkaesque’
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
